Strong Q1 Performance: Straumann Group reported CHF 681 million in revenue for Q1 2025, reflecting a robust organic growth of 11% year-over-year. This performance was driven by solid demand across all business segments, particularly in the EMEA and APAC regions, despite macroeconomic uncertainties.

Regional Dynamics and Challenges: The EMEA region exhibited exceptional growth due to increasing patient spending, improved reimbursement rates, and market penetration. APAC, particularly outside of China, also showed robust performance. Conversely, North America faced soft demand amid economic challenges, leading to more volatile customer sentiment.

Product Innovation as Growth Driver: Key product launches, such as the new iEXCEL implant system, entry-level SIRIOS intraoral scanner, and the collaboration with SprintRay on chairside 3D printing, are expected to significantly impact growth over the next 12-24 months. The company is focusing on enhancing its digital solutions to improve customer experience and streamline workflows.